The latest price target for AC Immune (NASDAQ:ACIU) was reported by HC Wainwright & Co. on November 15, 2024. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 447.96% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ:ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

There is no last upgrade for AC Immune

There is no last downgrade for AC Immune.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $16.00 to $16.00. The current price AC Immune (ACIU) is trading at is $2.92, which is out of the analyst’s predicted range.